Astellas

Astellas Pharma Inc.

Company type	Public
Traded as	Template:TYO
Industry	Pharmaceutical
Founded	April 1, 2005
Key people	Kenji Yasukawa (President and CEO)
Products	Prescription drugs
Revenue	¥1.3 trillion (2022)
Number of employees	15,000 (2022)
Website	www.astellas.com

Astellas Pharma Inc. is a global pharmaceutical company headquartered in Tokyo, Japan. It was formed on April 1, 2005, through the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd.. Astellas is dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.

History

Astellas Pharma was established as a result of the merger between Yamanouchi and Fujisawa, two of Japan's leading pharmaceutical companies. The merger was aimed at creating a more competitive and efficient company capable of thriving in the global market. Since its inception, Astellas has focused on research and development, particularly in the fields of urology, oncology, immunology, and neuroscience.

Research and Development

Astellas invests heavily in research and development (R&D) to discover and develop new drugs. The company operates several R&D centers around the world, including facilities in Japan, the United States, and Europe. Astellas' R&D efforts are focused on areas with high unmet medical needs, such as cancer, kidney diseases, and infectious diseases.

Products

Astellas offers a wide range of pharmaceutical products, including treatments for prostate cancer, overactive bladder, and transplant rejection. Some of its well-known products include:

• Xtandi (enzalutamide) - used in the treatment of prostate cancer.
• Vesicare (solifenacin) - used to treat overactive bladder.
• Prograf (tacrolimus) - an immunosuppressant used to prevent organ transplant rejection.

Corporate Social Responsibility

Astellas is committed to corporate social responsibility (CSR) and sustainability. The company engages in various initiatives to improve access to healthcare, support communities, and reduce its environmental impact. Astellas also supports educational programs and research initiatives to advance medical knowledge and innovation.

Global Presence

Astellas operates in over 70 countries worldwide, with a strong presence in North America, Europe, and Asia. The company continues to expand its global footprint through strategic partnerships, acquisitions, and collaborations with other pharmaceutical companies and research institutions.

Also see

• Pharmaceutical industry
• Drug development
• Biotechnology
• Merger and acquisition